Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | EED | O75530 | 9/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5421412 | 0.81 | LMNA (0.38) | LMNA | |
| SCHEMBL28042949 | 0.80 | LMNA (0.36) | LMNAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL17311290 | 0.78 | LMNA (0.34) | LMNA | |
| SCHEMBL5421634 | 0.75 | LMNA (0.38) | LMNA | |
| SCHEMBL31038078 | 0.74 | EED (0.40) | EEDKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL22363092 | 0.74 | EED (0.40) | EEDKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5417502 | 0.74 | EED (0.36) | EEDKDM4EALDH1A1 | |
| SCHEMBL28616526 | 0.74 | EED (0.39) | EEDKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL7535391 | 0.73 | IDO1 (0.48) | LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL20238554 | 0.73 | EED (0.38) | EEDKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271264-B2 | Pentacyclic oxepines and derivatives thereof, compositions and methods | ELI LILLY AND COMPANY (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271264-B2 | Pentacyclic oxepines and derivatives thereof, compositions and methods | ELI LILLY AND COMPANY (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271264-B2 | Pentacyclic oxepines and derivatives thereof, compositions and methods | ELI LILLY AND COMPANY (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1551822-B1 | PENTACYCLIC OXEPINES AND DERIVATIVES THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LILLY CO ELI (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20050261277-A1 | Pentacyclic oxepines and derivatives thereof, compositions and methods | ELI LILLY AND COMPANY | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261277-A1 | Pentacyclic oxepines and derivatives thereof, compositions and methods | NR5A1, NR3C2, OXER1 | LMNA 3458/4885EED 962/4885KDM4E 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.